News

Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024

MINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of…

2 years ago

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO…

2 years ago

ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System

Limited Market Release of First Purpose-Built OR Product to Begin in First Half of 2024 SmartFrame OR™ Stereotactic Systemwww.clearpointneuro.com SOLANA…

2 years ago

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents…

2 years ago

Biora Therapeutics Provides Outlook for 2024

Multiple catalysts anticipated in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships…

2 years ago

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress

Oak Ridge, TN, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement…

2 years ago

Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication

-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024- -Marks the first IND for Aruna’s…

2 years ago

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

WASHINGTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical…

2 years ago

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering…

2 years ago

Single Use Support continues to grow, expanding its team by 40%

Innovative process solution provider Single Use Support continues to deliver strong organic growth, supported by an expansion in its employee…

2 years ago